Subscribe To

Price Alert Latest News Economic Calendar News

CTMX / CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Read More

Demo Live Account See Partner Details

Content Topics

Cytomx

Therapeutics

Report

Fourth

Quarter

Full

Year

2022

Financial

Results

Stock

CTMX

Posted: Mar 22 2023, 19:23

Author Name: GlobeNewsWire

CTMX News

By GlobeNewsWire
September 5, 2023

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activ

By Zacks Investment Research
August 25, 2023

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this tec

By Seeking Alpha
August 8, 2023

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice Pres

By Zacks Investment Research
August 8, 2023

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to

By GlobeNewsWire
June 1, 2023

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activa

By Seeking Alpha
May 9, 2023

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Acco

By Zacks Investment Research
May 9, 2023

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to

By Seeking Alpha
March 27, 2023

CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2022 Earnings Conference Call March 27, 2023 5:00 PM ET Company Participants Chris Ogden - SVP of Finance

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.